魯抗醫藥(600789.SH):募投項目結項 節餘募集資金永久補充流動資金
格隆匯3月10日丨魯抗醫藥(600789.SH)公佈,公司非公開發行股票募投項目已全部實施完畢。本次結項的募集資金投資項目為“生物醫藥循環經濟產業園人用合成原料藥技術升級項目”、“高端生物獸藥建設項目”、“特色發酵原料藥建設項目”。其中“生物醫藥循環經濟產業園人用合成原料藥技術升級項目”、“特色發酵原料藥建設項目”已經完成工程建設,但尚需支付工程及設備尾款418.98萬元。本次結項後,公司非公開發行募投項目已全部實施完畢。
募投項目結項後節餘募集資金用途:扣除尚需支付的工程及設備尾款418.98萬元,公司非公開發行股票募投項目節餘募集資金為8055.86萬元(實際餘額以資金轉出時專户餘額為準),公司擬將節餘募集資金永久補充流動資金,用於公司日常生產經營。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.